Sona Nanotech Inc. (SNANF)
OTCMKTS
· Delayed Price · Currency is USD
0.188
0.00 (0.00%)
Nov 29, 2024, 4:00 PM EST
Sona Nanotech Company Description
Sona Nanotech Inc. operates as a nanotechnology life sciences company.
It develops targeted hyperthermia therapy for cancer treatment; and nanomedical therapy for the treatment of colorectal cancer.
The company also develops gold nanoparticle products; lateral flow assay rapid tests; bovine TB tests; and concussion screening tests.
Sona Nanotech Inc. was founded in 2013 and is based in Halifax, Canada.
Sona Nanotech Inc.
| Country | Canada |
| Founded | 2013 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| CEO | David Regan |
Contact Details
Address: Purdy’s Wharf Tower II Halifax, B3J 3R7 Canada | |
| Phone | 902 442 0653 |
| Website | sonanano.com |
Stock Details
| Ticker Symbol | SNANF |
| Exchange | OTCMKTS |
| Fiscal Year | November - October |
| Reporting Currency | CAD |
| ISIN Number | CA83541C1059 |
| SIC Code | 1000 |
Key Executives
| Name | Position |
|---|---|
| David Andrew Regan | Chief Executive Officer |
| Robert William George Randall CPA | Chief Financial Officer and Corporate Secretary |
| Dr. Len Pagliaro Ph.D. | CSO and Director |
| Dr. Kulbir Singh Ph.D. | Co-Founder and Head of Research & Development |
| Dr. Mike McAlduff | Director of Research & Development and Production and Founder |
| Dr. Gerrard Marangoni | Co-Founder and Member of Scientific Advisory Board |
| Darren Rowles | Head of Diagnostics |
| Dr. Carman Giacomantonio M.D., M.Sc. | Chief Medical Officer |